NEXTCURE, INC Cash and Restricted Cash
NEXTCURE, INC (NXTC) had Cash and Restricted Cash of $15.26 million as of 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-18
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.26M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.17M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $25.98M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.32M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $15.26M S-4 · filed 2026-08-18 | |
| 2026-03-31 | $15.17M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $25.98M S-4 · filed 2026-08-18 | |
| 2025-09-30 | $7.32M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $4.89M S-4 · filed 2026-08-18 | |
| 2025-03-31 | $21.83M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $27.73M S-4 · filed 2026-08-18 | |
| 2024-09-30 | $27.70M 10-Q · filed 2025-11-05 | $27.70M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $20.85M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $18.36M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $13.08M S-4 · filed 2026-08-18 | |
| 2023-09-30 | $19.52M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $22.02M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $29.97M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $26.63M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $31.09M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $28.20M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $10.69M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $12.34M 10-K · filed 2024-03-21 | $12.38M 10-K · filed 2022-03-03 |
| 2021-09-30 | $36.70M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $37.58M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $39.62M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $36.28M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $26.46M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $29.39M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $33.67M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $39.13M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $14.97M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $197.73M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $130.59M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $135.63M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $24.34M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $29.47M 10-Q · filed 2019-08-12 | |
| 2018-03-31 | $3.92M 10-Q · filed 2019-06-10 | |
| 2017-12-31 | $9.29M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |